Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Assess the impact of pre-transplant prostate cancer on mortality after lung transplant and the incidence of recurrence of prostate cancer after transplant.
The electronic medical records were reviewed for patients that underwent lung transplant from January 1, 1997 to December 31, 2012 at our center. Individuals were included in this retrospective study if they were male, ≥ 50 years of age at transplant, and undergoing first lung transplant. Collected information included history of prostate cancer, time interval from cancer diagnosis to transplant, recurrence of prostate cancer post-transplant, last follow up date and mortality status as of December 31, 2014. We used the Kaplan-Meier curve and log-rank test to assess mortality difference between individuals with and without a history of prostate cancer.
From January 1, 1997 to December 31, 2012, 1054 transplants were performed and 465 patients were included in the analysis. Thirteen individuals (2.8%) had a history of prostate cancer prior to transplant with median interval from diagnosis of prostate cancer to lung transplant of 43 months (range 6-228). Patients were followed for a median of 24.4 months (range 0.7-64.6) post-transplant and 5 (38.5%) were alive at the end of follow up. No patients had recurrence of prostate cancer. Log-rank test did not demonstrate a statistically significant difference in mortality (p=0.08) in those with and without a history of prostate cancer prior to lung transplant with Kaplan-Meier curve below (Figure 1).
We did not find a significant impact of pre-transplant prostate cancer on post-transplant mortality in those who have undergone lung transplant. Due to the low prevalence of prostate cancer in our cohort, we were unable to perform a multivariable analysis to account for confounders. There were no instances of recurrence of prostate cancer after lung transplant, including in the 5 individuals who underwent transplant less than 2 years after prostate cancer diagnosis. Further studies are needed to describe this cohort further.
Figure 1: Kaplan-Meier survival curve for those with and without a history of prostate cancer prior to transplantation.
CITATION INFORMATION: Ajani S, Valapour M, Budev M. Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Ajani S, Valapour M, Budev M. Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/pre-transplant-prostate-cancer-in-lung-transplant-recipients-and-impact-on-post-transplant-morbidity-and-mortality/. Accessed March 5, 2021.
« Back to 2016 American Transplant Congress